India's pharma cohort had a landmark deal on the wire on Monday, and the stocks fell anyway. Three Indian forces pulled the Nifty down 0.70% to 23,382 — the US-Iran 60-day framework slipped (Brent up over 3%), the monsoon scare hit FMCG, and MPC-week de-risk ran ahead of Friday's quadruple-event day. Broad emerging markets rallied over 2%; India sat conspicuously below. The Glenmark-AbbVie $700 million bispecific-antibody deal answered Friday's open question — and the answer carries a structural read for the whole Indian pharma cohort.

• Broad EM rallied over 2%, but Nifty fell 0.70% — India-specific drivers, not global flow.

• PTC Industries +14% led gainers on Q4 PAT +143% YoY; Goldman Buy with ₹25,770 target.

• JP Power −14% was the biggest fall — profit-booking unwind of the May 21 Adani Power 24% stake-deal rally.

• MTAR Technologies −10% — momentum reversal after a 165% YTD run, no fresh negative news.

• Glenmark fell 3.6% after the AbbVie deal — Indian pharma is still valued as a generic-formulations cohort.

• Friday June 5 is the week's defining session: RBI MPC, Q4 GDP, Governor's presser, US NFP.

This is general market commentary, not investment advice or a recommendation to buy or sell any security. The author may hold positions in stocks mentioned and has not disclosed them. Past performance does not predict future results. SEBI Research Analyst registration is in process and has not yet been granted. For investment advice tailored to your personal situation, consult a SEBI-registered Investment Adviser (RIA). Markets are risky; you may lose money; act with care.

Nimit Mehra, CFA L3

Narration is AI-generated using Sarvam TTS; script and analysis are by Nimit Mehra.

Key pointsDisclaimerBylineAI-narration disclosure